Advertisement

US To Pay Pfizer, BioNTech $1.95 Billion For Millions Of Covid-19 Vaccine Doses

Follow The Hawk on Google News+ Follow

Advertisement


Wshington: Pfizer Inc and German biotech firm BioNTech SE will get $1.95 billion from the US government to produce and deliver 100 million doses of their COVID-19 vaccine candidate, the companies said on Wednesday.

The agreement allows the US government to acquire an additional 500 million doses, the Department of Health and Human Services and the Department of Defense said.

Advertisement

The Trump administration has agreed to spend billions of dollars for the development and procurement of a potential vaccine. The administration launched 'Operation Warp Speed' — a joint HHS and Department of Defense program — to accelerate the development of coronavirus vaccines, treatments and diagnostics.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

More than 150 coronavirus vaccines using a variety of technologies are in development globally, with some two dozen already in human trials. Governments have signed deals with drugmakers to secure the supply of various vaccine candidates.

The aim is to produce vaccines that can end the pandemic by protecting billions of people from infection or severe illness.

Advertisement

Pfizer and BioNTech's vaccine candidate is among those that are set to be tested in a large trial. The vaccine has shown promise in early-stage small studies in humans.

Also read'Fatty liver-free campaign' in Ranchi from Nov 23, MoS Sanjay Seth to take lead

Pfizer will deliver the doses if the product receives Emergency Use Authorization or licensure from the US Food and Drug Administration, after completing demonstration of safety and efficacy in a large Phase 3 clinical trial.

The companies said they expect to be ready to seek some form of regulatory approval as early as October, if the ongoing studies are successful.

Pfizer and BioNTech currently expect to manufacture up to 100 million doses globally by the end of 2020, and potentially more than 1.3 billion doses by the end of 2021, subject to final dose selection from their clinical trial.

Pfizer's shares rose 4%, while BioNTech's US-listed shares were up about 6% before the bell.

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST